Silver Spring’s United Therapeutics Secures License Agreement With Eli Lilly For Lung Treatment Drug
Silver Spring-based United Therapeutics Corporation extended an agreement with Eli Lilly for the fifth drug in its product line.
Adcirca also known as tadalafil, brought in $12.5 million for United Therapeutics in the first quarter of 2020.
United Therapeutics was able to turn the drug — originally used to treat erectile dysfunction — into a treatment for pulmonary arterial hypertension (PAH). It improves patients shortness of breath and exercise ability.
The exclusive license agreement was set to expire on December 31, 2020 but has been extended to December 31, 2023.